Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Manisty, Charlotte; Otter, Ashley; Treibel, Thomas A.; McKnight, Áine; Altmann, Daniel M.; Brooks, Timothy; Noursadeghi, Mahdad; Boyton, Rosemary J.; Semper, Amanda; Moon, James

doi:10.1016/s0140-6736(21)00501-8

Cited by 400 publications

(434 citation statements)

References 4 publications

Supporting

Mentioning

332

Contrasting

Unclassified

Order By: Relevance

“…Finally, and as reported by others [4, 5], analysis of participants previously exposed to SARS-CoV-2 confirmed the 1 st vaccination dose acts as a boost. The full cohort encompassed 31 participants who tested anti-N positive at d0 and complied with the 3 collections schedules.…”

Section: Resultssupporting

confidence: 84%

Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges

Viana

Bergman

Gonçalves

et al. 2021

Preprint

View full text Add to dashboard Cite

While mRNA vaccines authorised for emergency use are administrated worldwide in an effort to contain the COVID19 crisis, little is known about the heterogeneity of the immune response they induce. Here, we report the first 6 weeks of a longitudinal study that quantifies the humoral immune response to BNT162b2 mRNA COVID-19 (Pfizer/BioNTech, Comirnaty) in 1245 health care providers, the Lx1000HCW-PZF cohort. We reveal a striking inter-individual variation 3 weeks after the 1st dose administration that only in part related to age and sex. While population homogeneity in robust IgG responses was reached upon 2nd dose administration, IgM and IgA levels remain low and heterogenous. Our findings of isotypic and heterogenous antibody responses to Comirnaty highlight the need for evaluating the efficacy of COVID-19 mRNA vaccine in preventing infection aside disease, and - contrary to what has been proposed - advocate for the interval between the two doses not to be extended.

show abstract

Section: Resultssupporting

confidence: 84%

Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges

Viana

Bergman

Gonçalves

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Although we have not assessed the presence of neutralizing antibodies, our results reinforce preliminary reports with a small number of cases [3–6]. This robust serologic response is highly correlated to the presence of neutralizing antibodies [8].…”

Section: Discussionsupporting

confidence: 88%

“…Our work provides some additional interesting data. First HCW who had lost their SARS-CoV-2 antibodies exhibit a lower response, that might be insufficient to provide SARS-CoV-2 protection[3,8]. Conversely, the combination of clinical COVID-19 and the presence of anti-Spike-IgG SARS-COV-2 antibodies before vaccination are strong predictors of a robust serologic response to a single dose of the mRNA vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…In this setting, a strategy to use single-dose of mRNA vaccines for some individuals could accelerate the achievement of this goal. Data on immune responses to single-dose vaccination with BNT162b2 are limited to few observational studies with small number of patients [3–6]. Moreover, impact of previous natural infection on vaccine response is not well known.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine

Velasco

Galín

Casas

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Indeed, in most countries individuals who recovered from SARS-CoV-2 infection are not excluded from COVID-19 vaccination, and they commonly follow two-doses vaccination schedule [13-14]. However, differently from naïve individuals, these data suggest that one single injection may be sufficient to protect ex COVID-19 subjects in accordance with emerging data [15-16]. We also cannot exclude that the second jab might even be detrimental in this context, leading to a functional exhaustion of spike-specific lymphocytes [17].…”

Section: Resultsmentioning

confidence: 55%

First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in ex COVID-19 subjects

Mazzoni

Lauria

Maggi

et al. 2021

Preprint

View full text Add to dashboard Cite

Characterizing the adaptive immune response to COVID-19 vaccination in individuals who recovered from SARS-CoV-2 infection may define current and future clinical practice. To determine the effect of two doses BNT162b2 mRNA COVID-19 vaccination schedule in individuals who recovered from COVID-19 (ex COVID-19) compared to naive subjects we evaluated SARS-CoV-2 spike-specific T and B cell responses, as well as specific IgG, IgM and neutralizing antibodies titres in 22 individuals who received BNT162b2 mRNA COVID-19 vaccine, 11 of which had a previous history of SARS-CoV-2 infection. Evaluations were performed before vaccination and then weekly until 7 days post second injection. Data obtained clearly showed that one vaccine dose is sufficient to increase both cellular and humoral immune response in ex COVID-19 subjects without any additional improvement after the second dose. On the contrary, the second dose is mandatory in naive ones to further enhance the response. These results question whether a second vaccine jab in ex COVID-19 subjects is required and indicate that millions of vaccine doses may be redirected to naive individuals, thus shortening the time to reach herd immunity.

show abstract

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Cited by 400 publications

References 4 publications

Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges

Population homogeneity for the antibody response to COVID-19 BNT162b2 / Comirnaty vaccine is only reached after the second dose, across all adult age ranges

Impact of previous COVID-19 on immune response after a single dose of BNT162b2 SARS-CoV-2 vaccine

First dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in ex COVID-19 subjects

Contact Info

Product

Resources

About